Aktis Oncology reports Q2 2026 results, three Phase 1b trials now underway or clearedAug 13Quarterly updateAktis Oncology, Inc.
FDA approves supplement 37 for Novartis's PluvictoJul 31Regulatory decisionlutetium lu 177 vipivotide tetraxetanNovartis
Novartis posts pelacarsen Phase 3 apheresis results, updates three drug labelsJul 17Weekly roundup, 8 itemscarbamazepineimatinib
Sign inSign in